en · de · es · pt
aod-9604-notes.peptides6608.com › Info › Background And Molecular Identity — Common Mistakes

Background And Molecular Identity — Common Mistakes

By Editorial Desk · published 2025-11-08 · last reviewed 2025-11-22 · Info

mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-11-22 and is reviewed periodically as new material appears.

Background and Molecular Identity

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideBased on the C-terminal region of human growth hormone.
Amino acid length16 residuesOften described as hGH fragment 176-191.
AppearanceLyophilized powderTypically white to off-white; exact appearance depends on grade.
SolubilitySoluble in waterAqueous solubility depends on pH, ionic strength, and preparation.
Typical storage-20 °C or lowerLyophilized peptide is usually kept cold and dry; solutions may require freezing.

Handling And Analytical Properties

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Related pages on this site

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Handling, Analysis, and Quality Control

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Further detail

The discovery in 1857 by William Henry Perkin that aniline could be used to make intense colouring agents had led to the commercial production of synthetic dyes in England from aniline extracted from coal tar. BASF recruited Heinrich Caro, a German chemist with experience of the dyestuff industry in England, to be the first head of research. Caro developed a synthesis for alizarin (a red dye used for dying textile fabrics) and applied for a British patent on 25 June 1869. Coincidentally, Perkin applied for a virtually identical patent on 26 June 1869, and the two companies came to a mutual commercial agreement about the process. Further patents were granted for the synthesis of methylene blue and eosin, and in 1880, research began to try to find a synthetic process for indigo dye, though this was not successfully brought to the market until 1897. In 1901, some 80% of the BASF production was dyestuffs.

Shorter D-stem: To understand the role of the unusual long D-stem in tRNASec, artificial variants with shorter D-stems were put into E. coli. It turns out that these variants work faster than the standard version at regular temperatures but easily lose function at high temperatures. This suggests that the long D-stem evolved as an adaptation to high temperature. Removal of SelB and SECIS requirement: In 2013, a new kind of tRNA was artificially created by putting the acceptor stem and CUA anticodon of E. coli tRNASec on the backbone of E. coli tRNASer. This new tRNAUTu can be recognized by ordinary EF-Tu, removing the requirement for SelB and SECIS for elongation. However, about 40% of the insertions were serine instead of selenocystine, suggesting that SelA is not efficiently recognizing this tRNA. In 2014, directed evolution was used to greatly improve the ability of tRNAUTu to be recognized by SelA, achieving a version that results in no detected misincorporation of serine. This enables simple replacement of any residue by Sec in future protein engineering efforts. By 2018, the E. coli system has matured to be suitable for "industrial scale" production. In one case this was achieved by laborotaory evolution. In another case this was achieved by incorporating elements of allo-tRNAs. The tRNAUTu system was adapted to Saccharomyces cerevisiae (yeast), which has no natural selenocystine system, in 2023. A mixture of bacterial and mouse enzymes work on a modified yeast tRNASer, which is able to be recognized by eEF1A.

The US has used its dominant power to enforce the conventions in other countries, in ways that include making financial aid contingent on drug control efforts, and supplying economic and military support for drug intervention. The drug conventions do not explicitly prohibit, they establish control over a set of drugs. The personal use of illicit drugs is not outlawed, although possession is. Penalties are not specified, they are at the discretion of individual countries, and can range from mild to harsh. In practice, this flexibility has been used to create a prohibitionist, punitive war on drugs that is not explicitly required by the treaties. Negative effects of this hardline approach – increased violence and organized crime; human rights violations – have led to an increasing number of countries deviating from the regime. Deviation undermines the credibility of the drug conventions, which in turn, can weaken the entire system of UN international treaties.

== Research == Hicks' research focuses largely on the development and implementation of mass spectrometric methods for protein identification and characterization. Recent work in the Hicks Lab has focused primarily on two areas. The first is the study of post-translational modifications and their role in regulation and development. The second involves a novel analytical pipeline for the discovery and characterization of antimicrobial peptides. Hicks' research in post-translational modifications typically employs bottom-up proteomics using label-free quantification. Much of this research involves the model organism C. reinhardtii, an important organism in biofuel research due to its tendency to accumulate triacylglycerols. The Hicks Lab has studied the phosphoproteome of C. reinhardtii in order to examine underlying biological processes. Work has also been done to understand cell regulatory pathways, especially the algal analog of the mammalian TOR pathway. To a similar end, Hicks' group has extended its work to examine how the reversible oxidation of thiols plays a role in signaling and effector-triggered immunity. The increasing threat of antimicrobial resistance has produced a need for novel antimicrobial agents. The Hicks Lab has investigated antimicrobial peptides as a potential source for new antibiotics. Recent work has involved the development of a comprehensive analytical approach using LC-MS for the identification of novel antimicrobial peptides from botanical, fungal, and bacterial sources.

Sources: en.wikipedia.org

Supporting material

== Green bean chips == Green bean chips may be prepared mixed with olive oil and seasonings, which are placed on a baking pan and baked until they are crisp. They may be prepared by freeze-drying green beans that are then vacuum-fried. Per a one-ounce (30 g) serving, green bean chips contain 130 calories, 4.5 g fat and 5 g fiber.

== History == As early as the 17th century, the Spanish used quinine from the bark of Cinchona trees to treat malaria after being shown the remedy from the Indigenous peoples of Peru, Bolivia, and Ecuador. In early 19th century India and other tropical posts of the British Empire, medicinal quinine was recommended to British officials and soldiers to prevent malaria, where it was mixed with soda and sugar to mask its bitter taste, creating tonic water. The first commercial tonic water was produced in 1858 when a new invention "An improved aerated liquid" known as Quinine Tonic Water was patented by the owner of Pitt & Co., Erasmus Bond and manufactured at their Wharf Road, City Road London factory. The mixed drink gin and tonic also originated in British colonial India, when the British mixed their medicinal quinine tonic with gin and other ingredients to make the bitter medicine more palatable. Soldiers in India were already given a gin ration, so the concoction was easy to make. In 1868, the first known record of a gin and tonic was in the Oriental Sporting Magazine and was described as a refreshing cocktail for spectators of horse racing, not as a medicine.

== Regulation == The regulation of the glyoxylate cycle involves carbon source availability, as it controls the transcriptional levels of key enzymes. Carbon catabolite repression is the main process that occurs in bacteria and fungi that regulates the transcriptional levels of the glyoxylate cycle, ensuring that the cycle is activated when glucose is not available. For instance, in Escherichia coli, the regulation of the isocitrate branch point takes place by regulating the transcription level of IclR and FadR, and through AceK, which is a bifunctional enzyme that acts as both a dehydrogenase kinase and a phosphatase. AceK is responsible for the regulation of isocitrate dehydrogenase and its switching roles in the citric acid cycle as well as the glyoxylate cycle. It determines whether the carbon atoms will be used in the glyoxylate cycle or the citric acid cycle. The phosphorylation, catalyzed by the AceK kinase function, of isocitrate dehydrogenase decreases its activity, and this phosphorylation can be reversed. In plants, the regulation of the glyoxylate cycle is achieved by regulating transcriptional levels during the seed germination process and through the mobilization of stored lipids . In bacteria, such as Mycobacterium tuberculosis, the glyoxylate cycle is up regulated especially when glucose is scarce and is needed during host infection. This regulation contributes to the growth and virulence of the pathogenic infection. Overall, these regulations allow for the conservation of carbon and activate the biosynthesis of key metabolites when carbon source is limited.

=== UK relaunch === In 2018, 40 years after the founding of SOLAR Records, the label was relaunched in the UK by the family of the late Dick Griffey, according to issue 77 of UK Publication 'Soul Survivors Magazine' which featured an interview with both Carrie Lucas and new CEO Jessie Tsang. At the helm of the relaunched label is Griffey's widow Carrie Lucas, his daughter Carolyn Griffey and British Chinese music promoter and IP paralegal consultant Jessie Tsang. Solar Records incorporates the Soul Train Records and Soul Train Club brands. Jessie Tsang is CEO with Sonia Damney as Vice President. In 2022 Carrie Lucas, Carolyn Griffey, Dina Andrews, Virgil Roberts participated with US Cable channel TV One for a special episode of the UNSUNG TV series on Dick Griffey and Solar Records. The episode premiered on November 6, 2022.

The habitat of pennyroyal is seasonally damp pasture, where standing water over the winter leaves bare ground in the summer, and where livestock preferentially graze other plants. An analogue of this habitat is found on roadsides, where trampling or disturbance of the ground produces similarly bare soil, particularly where there is waterlogging in winter. It is also found along watercourses, in wet woodland and in abandoned fields. In California, where it is considered an invasive species, it occupies a similar niche, in seeps, streamsides, vernal pools and swales, marshes, and ditches. There is some speculation that it may displace native species in these areas. Few animals eat pennyroyal. In Britain, the only insect known to feed on it is the bug Heterogaster artemisiae Schilling, which is a seed bug that normally feeds on wild thyme. It is considered an axiophyte in many British counties, because low-intensity pasture is a rare habitat, although it has been spreading in recent decades. Its Ellenberg values in Britain are L = 8, F = 7, R = 5, N = 7, and S = 0.

Sources: en.wikipedia.org

Supporting material

Eastern countries such as China and Russia and most Muslim nations like Iran, Indonesia and Pakistan remained staunchly opposed." The outcome document recommended treatment, prevention and other public health measures, and committed to "intensifying our efforts to prevent and counter" drug production and trafficking, through, "inter alia, more effective drug-related crime prevention and law enforcement measures." A statement signed by 189 civil society organizations criticized the 2016 outcome document, itemizing the lack of progress and calling out the "highly problematic, non-inclusive and non-transparent" process that made it possible for "a handful of vocal and regressive countries [to] block progressive language", resulting in "an expensive restatement of previous agreements and conventions".

Liquid scintillation counting is the measurement of radioactive activity of a sample material which uses the technique of mixing the active material with a liquid scintillator cocktail, and counting the resultant photon emissions. The purpose is to allow more efficient counting due to the intimate contact of the activity with the scintillator. It is generally used for alpha particle or beta particle detection.

== Interactions == Carbamazepine and other enzyme inducers may reduce plasma levels of risperidone. If a person is taking both carbamazepine and risperidone, the dose of risperidone will likely need to be increased. The new dose should not be more than twice the patient's original dose. CYP2D6 inhibitors, such as the SSRI medications fluoxetine and paroxetine, may increase plasma levels of risperidone. Since risperidone can cause hypotension, its use should be monitored closely when a patient is also taking antihypertensive medicines to avoid severe low blood pressure. Risperidone and its metabolite paliperidone are reduced in efficacy by P-glycoprotein inducers such as St John's wort. Risperidone has been found to dose-dependently block the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).

=== Unmelted sample analysis === Methods to analyze the microbe populations of colder, unmelted ice samples (cold enough to prevent brine drainage) under microscopes were developed by designing specialized equipment. Epifluorescence microscopes that can operate at subzero temperatures allowed researchers to observe undisturbed brine pool microbe populations with the addition of DAPI (DNA staining 4', 6-diamidino-2-phenylindole) mixed into an adequately salty and cold brine solution to highlight non-autofluorescing microbes. Alternatively, a microscope with a cold stage, commonly used to study glacial ice, may also be used to study unmelted sea ice with the right modifications. Other stains such as Alcian Blue (stains extracellular polysaccharide substances) and CTC (stains oxygen-respiring bacteria, 5-cyano-2,3-ditolyl tetrazolium) have also been used. Alcian Blue stains have revealed that extracellular polymeric substances (EPS) are ubiquitous throughout brine pools found in sea ice, even without any microbes visible in the brine pool. Some EPS originates from seawater before freezing but is also produced in copious amounts within algal bands and by bacteria to a lesser extent but throughout the entirety of the sea ice. CTC stains have indicated greater percentages of microbial activity within the sea ice when compared to the seawater below it, especially bacteria associated with particulate matter.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Is AOD-9604 the same as human growth hormone?

No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.

Does AOD-9604 occur naturally?

The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Network